Akebia reported Q4 2025 total revenues of USD 57.6 million and net product revenues of USD 54.3 million. Q4 net loss was USD 12.2 million. For FY 2025, total revenues were USD 236.2 million and net product revenues were USD 227.3 million, a 49% increase. FY net loss was USD 5.3 million, and cash and cash equivalents totaled USD 184.8 million at December 31, 2025. In Q4, Vafseo net product revenues were USD 6.2 million and Auryxia net product revenues were USD 48.1 million; FY 2025 Vafseo net product revenues were USD 45.8 million and Auryxia net product revenues were USD 181.5 million. Akebia said it expects Auryxia revenues to decrease in 2026 due to expanding generic competition, while it expects significant Vafseo revenue growth in 2026 driven by expanded access at dialysis organizations, new patient starts and improved adherence. Commercially, Akebia said Vafseo patient access stands at 290,000 patients; prescribers rose to about 800 in Q4 (up 10%), and about 25% of new patients in Q4 came from dialysis organizations other than U.S. Renal Care. In centers adopting in-center observed dosing, first refill adherence improved to 91% in Q4 from 75% in the first 9 months of 2025. Pipeline updates included enrollment underway in a Phase 2 praliciguat trial in focal segmental glomerulosclerosis, plans to start a Phase 2 open-label rare kidney disease basket study of AKB-097 in 2H 2026 with initial data expected in 2027, and a planned Phase 1 healthy volunteer study of AKB-9090 in H1 2026 with topline data expected by year-end.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260700PRIMZONEFULLFEED9661780) on February 26, 2026, and is solely responsible for the information contained therein.
Comments